CVS Health Co. (NYSE:CVS) Shares Sold by AXS Investments LLC

AXS Investments LLC trimmed its holdings in shares of CVS Health Co. (NYSE:CVS – Free Report) by 28.8% during the first quarter, Holdings Channel.com reports. The firm owned 5,209 shares of the pharmacy operator’s stock after selling 2,102 shares during the quarter. AXS Investments LLC’s holdings in CVS Health were worth $387,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Moneta Group Investment Advisors LLC boosted its stake in CVS Health by 103,371.0% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 15,547,559 shares of the pharmacy operator’s stock valued at $1,448,877,000 after buying an additional 15,532,533 shares in the last quarter. Norges Bank bought a new position in CVS Health during the fourth quarter valued at about $1,425,416,000. Morgan Stanley boosted its stake in CVS Health by 10.9% during the fourth quarter. Morgan Stanley now owns 33,576,388 shares of the pharmacy operator’s stock valued at $3,128,984,000 after buying an additional 3,311,928 shares in the last quarter. FMR LLC boosted its stake in CVS Health by 31.0% during the first quarter. FMR LLC now owns 13,666,949 shares of the pharmacy operator’s stock valued at $1,015,591,000 after buying an additional 3,237,567 shares in the last quarter. Finally, Capital Research Global Investors bought a new position in CVS Health during the first quarter valued at about $262,167,000. 75.99% of the stock is owned by institutional investors and hedge funds.

CVS Health Trading Up 0.8 %

Shares of NYSE CVS opened at $65.67 on Friday. CVS Health Co. has a one year low of $64.62 and a one year high of $104.83. The firm has a market capitalization of $84.35 billion, a PE ratio of 28.80, a PEG ratio of 1.27 and a beta of 0.63. The company has a current ratio of 0.86, a quick ratio of 0.64 and a debt-to-equity ratio of 0.84. The business has a 50-day moving average price of $71.10 and a two-hundred day moving average price of $73.18.

Want More Great Investing Ideas?

CVS Health (NYSE:CVS – Get Free Report) last posted its quarterly earnings results on Wednesday, August 2nd. The pharmacy operator reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.12 by $0.09. CVS Health had a return on equity of 15.43% and a net margin of 0.86%. The company had revenue of $88.92 billion during the quarter, compared to the consensus estimate of $86.41 billion. During the same period last year, the business earned $2.40 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, analysts predict that CVS Health Co. will post 8.62 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, August 1st. Stockholders of record on Friday, July 21st were paid a dividend of $0.605 per share. This represents a $2.42 dividend on an annualized basis and a dividend yield of 3.69%. The ex-dividend date of this dividend was Thursday, July 20th. CVS Health’s dividend payout ratio (DPR) is presently 106.14%.

Insider Transactions at CVS Health

In other news, SVP James David Clark sold 25,759 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $74.92, for a total transaction of $1,929,864.28. Following the completion of the sale, the senior vice president now directly owns 4,698 shares of the company’s stock, valued at approximately $351,974.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.25% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on CVS shares. Edward Jones cut CVS Health from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. Wells Fargo & Company decreased their price target on CVS Health from $95.00 to $76.00 in a research report on Monday, May 8th. Truist Financial decreased their price target on CVS Health from $103.00 to $98.00 and set a “buy” rating for the company in a research report on Thursday, August 3rd. Barclays decreased their price target on CVS Health from $89.00 to $86.00 and set an “overweight” rating for the company in a research report on Thursday, August 3rd. Finally, StockNews.com initiated coverage on CVS Health in a research report on Thursday, August 17th. They issued a “buy” rating for the company. Three research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $98.65.

View Our Latest Stock Report on CVS Health

CVS Health Company Profile

(Free Report)

CVS Health Corporation provides health services in the United States. It operates through Health Care Benefits, Pharmacy Services, and Retail/LTC segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.